α-glucosidase x GANC x MGAM

Main research purpose: This study aims to study the pharmacodynamic characteristics of acarbose tablets (specification: 50 mg) developed and produced by Shanghai Modern Pharmaceutical Co., Ltd. when taken orally under fasting conditions, and to compare the pharmacodynamic parameters of the two preparations and evaluate the bioequivalence of the two preparations in humans using acarbose tablets (Baytangping®, specification: 50 mg) certified by Bayer Healthcare Co., Ltd. as the reference preparation. Secondary research purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To study the pharmacodynamics of a single oral dose of the test preparation voglibose tablets (specification: 0.2 mg, produced by Zhejiang Jingxin Pharmaceutical Co., Ltd.) and the reference preparation voglibose tablets (Bexin®, specification: 0.2 mg, produced by Tianjin Takeda Pharmaceutical Co., Ltd.) in healthy participants under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting conditions. Secondary objective: To evaluate the safety of the test preparation voglibose tablets (specification: 0.2 mg) and the reference preparation voglibose tablets (Bexin®, specification: 0.2 mg) in healthy participants.